Advanced search
Start date
Betweenand

Targeting alternative ligand-binding sites in nuclear receptors using computational and experimental screening

Grant number: 14/03644-9
Support type:Scholarships in Brazil - Doctorate
Effective date (Start): November 01, 2014
Effective date (End): May 31, 2017
Field of knowledge:Biological Sciences - Pharmacology - Biochemical and Molecular Pharmacology
Cooperation agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
Principal researcher:Carsten Wrenger
Grantee:Thales Kronenberger
Home Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil
Associated scholarship(s):14/27313-1 - Targeting alternative ligand-binding sites in nuclear receptors using computational and experimental screening, BE.EP.DR

Abstract

Nuclear receptors are fundamental regulators of several biological processes in which they are controlling the transcription in eukaryotic cells that are modulated in a ligand-dependent manner. Besides the ligand-binding pocket there is experimental evidence of the existence of alternative ligand-binding sites on the surface of the ligand-binding domain which can be addressed by small organic molecules that disrupt specific protein-protein interactions and thereby may antagonize NR function. Mutational studies showed the importance of these sites for the functionality of the protein in vitro, and thereby validating their drug ability. Although the pharmacological potency is obvious there are no inhibitors under clinical investigation yet. This approach opens a door to develop a set of novel nuclear receptor modulators against several diseases such as cancer or diabetes. There is a large amount of structural information about the mechanism and regulation of NR and - in this sense - the implementation of computational approaches for drug screening combined with experimental high-throughputscreening (HTS) technologies will be a milestone in the identification of specific NRligand mimicking inhibitors. This project aims to use the combination of in silico and in vitro drug discovery approaches to interfere with alternative NR ligand binding sites in human cells. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications (8)
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
KRONENBERGER, THALES; ASSE, JR., LEONARDO RANDER; WRENGER, CARSTEN; GOULART TROSSINI, GUSTAVO HENRIQUE; HONORIO, KATHIA MARIA; MALTAROLLO, VINICIUS GONCALVES. Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses. Future Medicinal Chemistry, v. 9, n. 2, p. 135-151, . (14/03644-9, 13/10288-1)
BURK, OLIVER; KUZIKOV, MARIA; KRONENBERGER, THALES; JESKE, JUDITH; KEMINER, OLIVER; THASLER, WOLFGANG E.; SCHWAB, MATTHIAS; WRENGER, CARSTEN; WINDSHUEGEL, BJOERN. Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. ARCHIVES OF TOXICOLOGY, v. 92, n. 4, p. 1435-1451, . (14/27313-1, 14/03644-9)
KRONENBERGER, THALES; WINDSHUGEL, BJORN; WRENGER, CARSTEN; HONORIO, KATHIA M.; MALTAROLLO, VINICIUS G.. On the relationship of anthranilic derivatives structure and the FXR (Farnesoid X receptor) agonist activity. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, v. 36, n. 16, p. 4378-4391, . (14/03644-9, 14/27313-1)
MEISSNER, KAMILA ANNA; KRONENBERGER, THALES; MALTAROLLO, VINICIUS GONCALVES; GOULART TROSSINI, GUSTAVO HENRIQUE; WRENGER, CARSTEN. Targeting the Plasmodium falciparum plasmepsin V by ligand-based virtual screening. CHEMICAL BIOLOGY & DRUG DESIGN, v. 93, n. 3, p. 300-312, . (16/24790-9, 17/03966-4, 15/26722-8, 14/03644-9)
GAO, KAI; WANG, WENJIA; KRONENBERGER, THALES; WRENGER, CARSTEN; GROVES, MATTHEW R.. The Crystal Structure of the Plasmodium falciparum PdxK Provides an Experimental Model for Pro-Drug Activation. CRYSTALS, v. 9, n. 10, . (17/03966-4, 14/03644-9, 15/26722-8)
BURK, OLIVER; KRONENBERGER, THALES; KEMINER, OLIVER; LEE, SERENE M. L.; SCHIERGENS, TOBIAS S.; SCHWAB, MATTHIAS; WINDSHUEGEL, BJOERN. Nelfinavir and Its Active Metabolite M8 Are Partial Agonists and Competitive Antagonists of the Human Pregnane X Receptor. MOLECULAR PHARMACOLOGY, v. 99, n. 3, p. 184+, . (14/03644-9, 14/27313-1)
CANDIDO-FERREIRA, IVAN LAVANDER; KRONENBERGER, THALES; ROSA SAYEGH, RAPHAEL SANTA; CORREIA BATISTA, ISABEL DE FATIMA; DA SILVA JUNIOR, PEDRO ISMAEL. Evidence of an Antimicrobial Peptide Signature Encrypted in HECT E3 Ubiquitin Ligases. FRONTIERS IN IMMUNOLOGY, v. 7, . (14/03644-9, 13/07467-1)
MALTAROLLO, VINICIUS GONCALVES; KRONENBERGER, THALES; WINDSHUEGEL, BJOERN; WRENGER, CARSTEN; GOULART TROSSINI, GUSTAVO HENRIQUE; HONORIO, KATHIA MARIA. Advances and Challenges in Drug Design of PPAR delta Ligands. CURRENT DRUG TARGETS, v. 19, n. 2, p. 144-154, . (14/03644-9, 14/27313-1)
Academic Publications
(References retrieved automatically from State of São Paulo Research Institutions)
KRONENBERGER, Thales. Targeting alternative ligand-binding sites in nuclear receptors using computational and experimental screening.. 2017. Doctoral Thesis - Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB/SDI) São Paulo.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.